Pharmaceutical Executive, July 2022 Issue (PDF)
Articles in this issue
The True Nature of Danger Behind IP Waiver Proposal
In DOJ Crosshairs: Rethinking Commission-Based Deals With Independent Contractors
Cracking Down on Speaker Programs
Dynamic Compliance: The Best Defense for Pharma
A Steadying Force in C-Suite: The Changing Role of Biopharma CFOs
Breaking Down Barriers
Biotech Performance Glance—and Promising Ripples for Recovery
If Non-Formulary Hospital, Price May Not Be the Rx
When It Comes To DE&I, Silence Is Deafening
Asia’s Rise in The Global Pharma Industry
Rewriting European Regulations on Rare Disease Treatments
High-Value Views, Input
Pharmaceutical Executive, July 2022 Issue (PDF)
Orphan Drugs: From Niche to Mainstream
FDA Advances Quality Initiatives to Combat Drug Shortages
Recent Videos
Related Content
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Podcast
Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Podcast
Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
